Your session is about to expire
← Back to Search
LVGN6051 + Pembrolizumab for Metastatic Cancer
Study Summary
This trial is studying a new drug, LVGN6051, to see if it is safe and effective when given alone or with another drug, pembrolizumab (MK-3475), in treating patients with solid tumors that have spread to other parts of the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had a live-virus vaccine in the last 30 days.I've had a severe allergic reaction to a monoclonal antibody treatment.My cancer has spread to my brain or the membranes around my brain.I have had severe immune-related side effects from treatment.I have had a stem cell, bone marrow, or organ transplant.I am not pregnant or breastfeeding.I agree to use highly effective birth control methods.I am currently on an immune system-based treatment.My HIV is under control with effective treatment.I do not have any severe or uncontrolled illnesses.I haven't had radiotherapy in the last 14 days.I haven't taken any immune-stimulating drugs in the last 4 weeks.I have not needed IV antibiotics for an infection in the last 14 days.I have had a recent heart attack or unstable heart pain in the last 6 months.I am 18 years old or older.My bone marrow, liver, and kidneys are functioning well.I haven't taken any cancer treatment or experimental drugs recently.I have an autoimmune disease and have been treated for it in the last 2 years.I do not have any significant diseases or abnormal lab results.I have or had lung issues needing steroids for treatment.My cancer is confirmed to be advanced and cannot be removed by surgery.I have recovered from side effects of my previous cancer treatments.
- Group 1: LVGN6051
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What have been the outcomes of patients taking LVGN6051?
"Limited data exists to assess the safety and efficacy of LVGN6051, so it has been given a score of 1 on Power's rating scale."
Are there any available spots in this research trial for prospective participants?
"Affirmative. Clinicaltrials.gov indicates that this clinical trial, first posted on October 31st 2019, is still actively accepting applicants. The experiment requires 276 participants from a single medical centre."
What is the scope of participants in this research endeavor?
"Affirmative. The information on clinicaltrials.gov suggests that this medical trial, which was initially posted October 31st 2019, is currently recruiting patients. A total of 276 people need to be enlisted from a single site."
Share this study with friends
Copy Link
Messenger